Programa de Pós-graduação em Bioquímica, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina, Florianópolis, Brazil.
Programa de Pós-graduação em Neurociências, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina, Florianópolis, Brazil.
Purinergic Signal. 2021 Jun;17(2):247-254. doi: 10.1007/s11302-021-09765-y. Epub 2021 Feb 6.
6-Hydroxydopamine (6-OHDA) is the most used toxin in experimental Parkinson's disease (PD) models. 6-OHDA shows high affinity for the dopamine transporter and once inside the neuron, it accumulates and undergoes non-enzymatic auto-oxidation, promoting reactive oxygen species (ROS) formation and selective damage of catecholaminergic neurons. In this way, our group has established a 6-OHDA in vitro protocol with rat striatal slices as a rapid and effective model for screening of new drugs with protective effects against PD. We have shown that co-incubation with guanosine (GUO, 100 μM) prevented the 6-OHDA-induced damage in striatal slices. As the exact GUO mechanism of action remains unknown, the aim of this study was to investigate if adenosine A (AR) and/or A receptors (AR) are involved on GUO protective effects on striatal slices. Pre-incubation with DPCPX, an AR antagonist prevented guanosine effects on 6-OHDA-induced ROS formation and mitochondrial membrane potential depolarization, while CCPA, an AR agonist, did not alter GUO effects. Regarding AR, the antagonist SCH58261 had similar protective effect as GUO in ROS formation and mitochondrial membrane potential. Additionally, SCH58261 did not affect GUO protective effects. The AR agonist CGS21680, although, completely blocked GUO effects. Finally, the AR antagonist DPCPX, and the AR agonist CGS21680 also abolished the preventive guanosine effect on 6-OHDA-induced ATP levels decrease. These results reinforce previous evidence for a putative interaction of GUO with AR-AR heteromer as its molecular target and clearly indicate a dependence on adenosine receptors modulation to GUO protective effect.
6-羟多巴胺(6-OHDA)是实验性帕金森病(PD)模型中最常用的毒素。6-OHDA 对多巴胺转运体具有高亲和力,一旦进入神经元,它就会积累并进行非酶自动氧化,促进活性氧(ROS)的形成,并选择性地损伤儿茶酚胺能神经元。通过这种方式,我们的小组建立了一种 6-OHDA 体外大鼠纹状体切片方案,作为一种快速有效的筛选具有 PD 保护作用的新药的模型。我们已经表明,与鸟苷(GUO,100μM)共孵育可防止 6-OHDA 诱导的纹状体切片损伤。由于 GUO 的确切作用机制尚不清楚,本研究的目的是研究是否腺嘌呤 A(AR)和/或 A 受体(AR)参与了 GUO 对纹状体切片的保护作用。AR 拮抗剂 DPCPX 的预孵育可防止 GUO 对 6-OHDA 诱导的 ROS 形成和线粒体膜电位去极化的作用,而 AR 激动剂 CCPA 则不会改变 GUO 的作用。关于 AR,拮抗剂 SCH58261 在 ROS 形成和线粒体膜电位方面与 GUO 具有相似的保护作用。此外,SCH58261 不影响 GUO 的保护作用。AR 激动剂 CGS21680 虽然完全阻断了 GUO 的作用。最后,AR 拮抗剂 DPCPX 和 AR 激动剂 CGS21680 也消除了 GUO 对 6-OHDA 诱导的 ATP 水平降低的预防作用。这些结果进一步证实了 GUO 与 AR-AR 异源三聚体相互作用作为其分子靶点的假设,并明确表明 AR 调节对 GUO 保护作用的依赖性。